Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

Bullboard Posts

Post by carduon Apr 25, 2006 2:55pm

318 Views

Post# 10741852

Amazing!

ONC presents a webcast on April 4 on interim results and the stock tanks. The day before the AGM the stock tanks, albeit on low volume. I sincerely hope that management has something significant to say tomorrow and not the usual pollyana generalizations that BT is becoming infamous for. The market won't tolerate this situation much longer before the wolves come out.

Bullboard Posts

Meet Canopy USA’s new CEO, Brooks Jorgensen